Intrinsiqq
Cel-Sci Corporation logo

Cel-Sci Corporation

CVM

⊜ Compare

CEL-SCI's PRODUCT CANDIDATES CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine: 1) …

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$24M
EPS-$1.15
P/E-1.20
P/FCF-1.45
EV/EBITDA-1.15
FCF Yield–
Div. Yield–
Net Debt/FCF-0.1x
Cel-Sci Corporation intrinsic value
52-Week Range
$0.97$4.07

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$23M

▲ +5.6% YoY

Op. Margin

–

ROIC

-80.22%

▲ +13.4pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$17M

▲ +9.2% YoY

Op. Cash Flow (TTM)

-$17M

▲ +9.0% YoY

Net Debt

$1M

Cash & Equiv.

$7M

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CVM

CompareIntrinsic value
BCABBioAtla, Inc.
$2.00+0.00%0
ZIVOZivo Bioscience Inc.
$8.00+10.34%0
WINTWindtree Therapeutics Inc.
$0.00+0.00%10
ATYRAtyr Pharma Inc.
$6.18-6.79%10
ARMPArmata Pharmaceuticals Inc.
$3.14+1.62%30
VIVSVivoSim Labs, Inc.
$0.15+8.71%10
AIMAIM ImmunoTech Inc.
$0.16+0.63%15
INMBInmune Bio Inc.
$1.33+0.76%10

Cel-Sci (CVM) in three numbers

Quality score
0/100
Best check: revenue growth, -34.9%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-1.20
Negative: a loss over the last twelve months. Price to free cash flow -1.45.
Financials

Questions about Cel-Sci

Is Cel-Sci a high-quality business?

Cel-Sci scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at -34.9%. The Quality tab shows every check against its target.

Does Cel-Sci (CVM) pay a dividend?

No. Cel-Sci (CVM) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 10 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in CVM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CVM

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.